WRRFA
CompletedRisk Factors Affect Weight Loss Outcomes After Treatment.
Exploration of Effect Weight Loss Outcome Related to Factors After Treatment of Weight Loss (WRRFA).
Lead sponsor
Asset
Liraglutide
Subcutaneous · GLP-1 agonist
Listed sites
1
Recruiting sites
-
Actual enrollment
3,602
Study population
Bariatric Surgery, Obesity / overweight
Eligibility highlights
•BMI ≥30
Primary endpoint
•Proportion of failure weight loss
Registered trial locations
Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Who this study enrolls
Who can enroll
Study population text
More than 30 BMI obese patients consent to join the study.
Eligibility criteria
Inclusion 1.65 ≥ Age ≥ 20 years-old. 2.BMI ≥ 30. 3.Once attempted exercise or dietary control. 4.No cognitive deficiency and clear communication. 5. No severe psychotic disorders were evaluated by the psychiatrist. (e.g. schizophrenia, bipolar disorder, or severe depression).
6. Signing the informed consent form for clinical trials.
Exclusion
1. Once underwent bariatric surgery.
2. Once used the GLP-1 receptor agonist.
3. Pregnancy or preparation for pregnancy.
4. Once and presenting gastric cancer.
5. Presenting the other cancer.
6. The abnormal endocrine system causes diseases with obesity.
7. Major organ abnormalities (e.g., kidney failure, liver failure, heart failure, etc.).
8. Gastric ulcer, and severe gastroesophageal reflux.
9. Severe psychiatric disorders (schizophrenia, severe bipolar disorder, and depression, etc.).
10. Bulimia nervosa or anorexia nervosa.
11. Drug and alcohol abuse.
12. Helicobacter pylori is not for bariatric surgery.
13. The following diseases or conditions preclude the use of Contrave: 1)Uncontrolled hypertension, 2) History or current diagnosis of epilepsy, 3) Allergy to this medication, 4) Medications evaluated by a physician to interact with this drug (antidepressants, antipsychotics, liver medications, heart medications).
14. The following diseases or conditions preclude the use of GLP-1 medication: 1) History or current diagnosis of medullary thyroid carcinoma, 2)History or current diagnosis of Multiple Endocrine Neoplasia syndrome type 2, 3)Allergy to this medication, 4)Medications evaluated by a physician to interact with this drug (antidepressants, antipsychotics, liver medications, heart medications).
15. The following diseases or conditions preclude the use of Xenical medication: 1) History or current diagnosis of cholestasis, 2) Allergy to this medication, 3) Medications evaluated by a physician to interact with this drug (antidepressants, antipsychotics, liver medications, heart medications).
Endpoints (13)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Weight & body composition
4 endpointsThe proportion of failure weight loss
Time frame:Month 6, Year 1, Year 1.5, Year 2
threshold achievement, improvement
The percentage of total weight loss changes
Time frame:Follow-up 8 times (Baseline, Month 1, Month 3, Month 6, Month 9, Year 1, Year 1.5, Year 2) visit for all secondary outcome
Body weight, % change
percent change from baseline, improvement
Weight change
Time frame:Follow-up 8 times (Baseline, Month 1, Month 3, Month 6, Month 9, Year 1, Year 1.5, Year 2) visit for all secondary outcome
Body weight, absolute change (kg)
change from baseline, improvement
BMI change
Time frame:Follow-up 8 times (Baseline, Month 1, Month 3, Month 6, Month 9, Year 1, Year 1.5, Year 2) visit for all secondary outcome
BMI, change
change from baseline, improvement
Patient-reported / QoL
4 endpointsHealth quality of life change
Time frame:Follow-up 8 times (Baseline, Month 1, Month 3, Month 6, Month 9, Year 1, Year 1.5, Year 2) visit for all secondary outcome
change from baseline, improvement
Quality of life after weight loss treatment change
Time frame:Follow-up 8 times (Baseline, Month 1, Month 3, Month 6, Month 9, Year 1, Year 1.5, Year 2) visit for all secondary outcome
change from baseline, improvement
Eating behavior
Time frame:Follow-up 8 times (Baseline, Month 1, Month 3, Month 6, Month 9, Year 1, Year 1.5, Year 2) visit for all secondary outcome
change from baseline, improvement
Psychiatric status
Time frame:Follow-up 8 times (Baseline, Month 1, Month 3, Month 6, Month 9, Year 1, Year 1.5, Year 2) visit for all secondary outcome
change from baseline, improvement
Other clinical outcomes
2 endpointsExercise change
Time frame:Follow-up 8 times (Baseline, Month 1, Month 3, Month 6, Month 9, Year 1, Year 1.5, Year 2) visit for all secondary outcome
change from baseline, improvement
Food addiction
Time frame:Follow-up 8 times (Baseline, Month 1, Month 3, Month 6, Month 9, Year 1, Year 1.5, Year 2) visit for all secondary outcome
change from baseline, improvement
Other (unclassified)
3 endpointsPhysiological parameter change
Time frame:Follow-up 8 times (Baseline, Month 1, Month 3, Month 6, Month 9, Year 1, Year 1.5, Year 2) visit for all secondary outcome
change from baseline, improvement
The comorbidity remission rate.
Time frame:Follow-up 8 times (Baseline, Month 1, Month 3, Month 6, Month 9, Year 1, Year 1.5, Year 2) visit for all secondary outcome
threshold achievement, improvement
Complication events.
Time frame:Follow-up 8 times (Baseline, Month 1, Month 3, Month 6, Month 9, Year 1, Year 1.5, Year 2) visit for all secondary outcome
change from baseline, event
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.